Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance mutations during structured treatment interruptions.

Antiviral therapy - 1 Oct 2003

Yerly Sabine, Fagard Catherine, Günthard Huldrych F, Hirschel Bernard, Perrin Luc

Abstract excerpt

BACKGROUND: We assessed whether treatment interruptions induce selection of mutations associated with drug resistance in the Swiss-Spanish Intermittent Treatment Trial (SSITT). Patients had been on HAART without previous failure and had undetectable viraemia for at least 6 months. Their HAART was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Protease

Share to HIV Reverse Transcriptase

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 14640388

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-14640388-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance mutations during structured treatment interruptions.PMID 14640388Read ↗

Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.Semantic proximity Read ↗

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.Semantic proximity Read ↗

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.Semantic proximity Read ↗

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.Semantic proximity Read ↗

Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions.Semantic proximity Read ↗

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection.Semantic proximity Read ↗

Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?Semantic proximity Read ↗

Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.Semantic proximity Read ↗

Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.Semantic proximity Read ↗

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.Semantic proximity Read ↗

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.Semantic proximity Read ↗

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.